Foundayo IQVIA Week-Ending-May-15 Tracker: ~17,000 Prescriptions vs Wegovy Pill ~142,000 — Lilly's First Above-15K Print Narrows but Doesn't Close the Trajectory Gap
IQVIA's weekly prescription tracker for Foundayo (orforglipron) hit approximately 17,000 prescriptions for the week ending May 15, 2026, per Citi's Friday client note — Lilly's first above-15,000 weekly print since the April 6 launch. The week-by-week trajectory: 1,390 (Week 1), 3,707 (Week 2), 5,612 (Week 3), 7,335 (Week 4), 10,248 (Week 5), and ~17,000 in the new print. Novo Nordisk's Wegovy pill recorded roughly 142,000 prescriptions in the same week — the trajectory gap is narrowing as Foundayo's PBM coverage activates at the largest US plans but still remains 8.3x the Foundayo volume. Citi maintains $146M Foundayo Q2 revenue and $1.6B 2026 full-year estimates; the IQVIA print supports the trajectory. Lilly's late-May TV-advertising launch may amplify the next leg of Foundayo growth heading into mid-June.